Is this email not displaying correctly? View it in your browser.
Newswise - News for Journalists
Newswise Special Wire
Tuesday, September 27, 2016

Public edition |

Newswise Cancer Research Wire for 27-Sep-2016

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

For Some Lung Cancer Patients Receiving SBRT, One and Done Approach Works Best

A new study led by Anurag Singh, MD, of Roswell Park Cancer Institute and presented at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting suggests that a single high-intensity SBRT dose can be as effective as three slightly lower...

– Roswell Park Cancer Institute

ASTRO Annual Meeting

Unmet Need for Radiation Therapy Found Among Nearly Half of Eligible Cancer Patients in Nine Developing Countries

Although approximately 50 percent of cancer patients in developing countries need radiation therapy (RT) to treat their disease, up to half of these patients do not have access to it, according to research presented today at the 58th Annual Meeting o...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 26-Sep-2016 at 07:45 ET

Intervention Closes Racial Gap and Improves Treatment Rates for Early Stage Lung Cancer

Enhanced, culturally-competent communication with early stage lung cancer patients can narrow racial gaps in curative treatment completion and increase treatment rates for all races, according to research presented today at the 58th Annual Meeting of...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 26-Sep-2016 at 07:45 ET

SBRT Offers Prostate Cancer Patients High Cancer Control and Low Toxicity in Fewer Treatments

High dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity and excellent cancer control rates, according to research presented today a...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 26-Sep-2016 at 07:45 ET

Extremely Hypofractionated Radiation Therapy Shows Promising Toxicity Results for Intermediate Risk Prostate Cancer Patients

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely-hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional ...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 26-Sep-2016 at 08:00 ET

Widespread Adoption of SBRT Has Improved Survival Rates for Elderly Patients with Early Stage Lung Cancer

Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC) rose from roughly 40 to 60 percent over the past decade, concurrent with the increasing adoption of SBRT, a...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 26-Sep-2016 at 10:30 ET

Hypofractionated RT Can Reduce Treatment Time by One-Third with Comparable QOL for Prostate Cancer Patients

For men with early stage, low-risk prostate cancer, treatment with hypofractionated radiation therapy (RT) offers comparable health-related quality of life outcomes in one-third less treatment time than conventional RT, according to research presente...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 26-Sep-2016 at 14:15 ET

Cervical and Endometrial Cancer Patients Report Fewer Side Effects and Better Quality of Life with IMRT

Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy (RT...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 26-Sep-2016 at 14:15 ET

Newly Discovered Immune Cell Type Protects Against Lung Infections During Chemotherapy

St. Jude Children’s Research Hospital scientists have discovered a previously unrecognized form of macrophage in mice; the immune cells survived chemotherapy and protected against life-threatening lung infections....

– St. Jude Children's Research Hospital

Embargo expired on 26-Sep-2016 at 15:00 ET

Intermediate Risk Prostate Cancer May Be Well Controlled with Brachytherapy Alone

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external ...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 26-Sep-2016 at 14:15 ET

Study: Shortened Radiation Therapy Offers Similar Quality of Life for Low-Risk Prostate Cancer Patients

Low-risk prostate cancer patients may be able to undergo a shortened course of radiation therapy that cuts treatment by weeks and offers comparable outcomes and quality of life results as those who undergo longer treatment courses....

– Henry Ford Health System

ASTRO Annual Meeting

Embargo expired on 26-Sep-2016 at 14:15 ET

World's Most Sensitive Dark Matter Detector, What to Expect From the Coming Quantum Era and More in the Physics News Source Sponsored by AIP

Click here to go directly to the Physics News Source Sponsored by AIP....

– Newswise

Unknown Exposure to Second-Hand Smoke Associated with Increased Mortality

A new biomarker has identified known and unknown exposure to second-hand smoke and confirmed a strong association to increased mortality in non-smokers, according to a new study from the Icahn School of Medicine at Mount Sinai. The results, publishe...

– Mount Sinai Health System

Medulloblastoma Patients Should Receive Both Chemotherapy and Radiation Post-Surgery

In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival. ...

– Yale Cancer Center

Radiation Therapy and Radical Prostatectomy Further Explored for Initial Diagnosis of Advanced Prostate Cancer

A database study examining surgical removal of the prostate gland (radical prostatectomy) or a form of radiation therapy known as IMRT to treat prostate cancer that has spread to other parts of the body (metastatic) shows an association between each ...

– Rutgers Cancer Institute of New Jersey

ASTRO Annual Meeting, Sept-2016

Recycling Cancer-Fighting Tools; MU Researchers Working to Produce Vital Radioisotopes at a Cheaper Cost

According to the World Nuclear Association, more than 10,000 hospitals worldwide use radioisotopes in medicine. Molybdenum-99, the parent isotope of technetium-99m, is the most widely used radioisotope for the diagnosis and treatment of cancer. Howev...

– University of Missouri Health

Fatty Diet Activates Oldest Branch of Immune System, Causing Intestinal Tumors

A high-fat-diet-induced immune reaction causes inflammation leading to intestinal cancer in a mouse model – even among animals that are not obese. ...

– Perelman School of Medicine at the University of Pennsylvania

U54 CA116867, AI030040, AI068730, P40 RR012305

UCLA Health Experts Advisory for October

UCLA Health experts are available to discuss a wide variety of topics of interest for the month of October....

Expert Available

– University of California, Los Angeles (UCLA), Health Sciences

Dr. Mingzhao Xing Presents the Paul Starr Award Lecture

The recipient of the 2016 American Thyroid Association (ATA) Paul Starr Award Lecture is Mingzhao Xing, M.D., Ph.D., Professor of Medicine, Oncology, and Cellular and Molecular Medicine at Johns Hopkins University School of Medicine, Baltimore, MD. D...

Expert Available

– American Thyroid Association

Hypofractionated Radiation Therapy Can Halve Treatment Time for Poor Performance Status Lung Cancer Patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free sur...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 25-Sep-2016 at 10:00 ET

Advances in Radiation Therapy Have Improved Survival Rates for Early Stage Lung Cancer Patients

A new analysis of records in the Veteran’s Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in ...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 25-Sep-2016 at 13:15 ET

Post-Operative Stereotactic Radiosurgery a New Standard of Care for Patients with Resected Brain Metastases

For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline and better quality of life (QOL), compared to whole brain radiotherapy (WBR...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 25-Sep-2016 at 15:15 ET

Stereotactic Radiosurgery Decreases Rate of Post-Operative Local Recurrence for Brain Metastases

Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rate...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 25-Sep-2016 at 15:15 ET

Reduced Radiation Boost Volume Recommended but Craniospinal Axis Dose Remains Unchanged for Average-Risk Pediatric Medulloblastoma

In the largest trial conducted for average risk (A-R) medulloblastoma, survival rates following reduced radiation therapy (RT) boost volumes were comparable to standard treatment volumes for the primary tumor site but lower doses of craniospinal axis...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 25-Sep-2016 at 15:15 ET

Three Novel Intrinsic Subtypes of Prostate Cancer Identified

In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients ...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2016

Embargo expired on 25-Sep-2016 at 15:15 ET

Identical 5-Year-Old Twins with Identical Cancers

These twin brothers are experiencing the unimaginable together – battling cancer. ...

– University of Michigan Health System

New Hope in Fight Against Aggressive and Often Hard to Treat Brain Tumour

Researchers from the University of Southampton have discovered a potential way of stopping one of the most aggressive types of brain tumour from spreading, which could lead the way to better patient survival. ...

– University of Southampton

DOI: 10.1007/s12035-016-0053-6

Yale Team Compares Effectiveness of Four PD-L1 Tests

In a recent study, a Yale Cancer Center team compared the performance of the four available PD-L1 assay tests. They found that one of the assays failed to reveal comparable levels of PD-L1, a tumor-promoting protein, while three others revealed compa...

– Yale Cancer Center

Pembrolizumab Approval Is Tip of the Iceberg for Immunotherapy in HNSCC

Immunotherapy is a big change for head and neck cancer and there seems to be no doubt that there is activity for immunotherapies with pembrolizumab as well as nivolumab [Opdivo]” said Burtness, professor of Medicine at Yale Cancer Center....

– Yale Cancer Center

Mercy Medical Center in Baltimore Hosts 3rd International Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Symposium

Mercy Surgical Oncologist Dr. Vadim Gushchin leads symposium focusing on PIPAC, a new emerging field of research with major therapeutic potential for cancer patients. ...

– Mercy Medical Center, Baltimore

Swarms of Magnetic Bacteria Could Be Used to Deliver Drugs to Tumors

Researchers have recently shown that magnetic bacteria are a promising vehicle for more efficiently delivering tumor-fighting drugs. ...

– National Institute of Biomedical Imaging and Bioengineering

Nature Nanotechnology, Aug-2016; EB007506

Ludwig Study Exposes Key Requirement for Regulatory T Cell Function

A Ludwig Cancer Research study published online September 5th in Nature Immunology illuminates a key requirement for the function of regulatory T cells—immune cells that play a critical role in many biological processes, from suppressing inflammati...

– Ludwig Cancer Research

Nature Immunology, Sept-2016

One Single Biopsy Not Sufficient to Guide Treatment Decisions in Prostate Cancer

Molecular composition of multiple tumors shows genomic differences....

– Cleveland Clinic

European Urology

September 2016 Health and Wellness Tips

Health and wellness tips about diabetes during pregnancy, kids nutrition, and colon cancer. ...

– UT Southwestern Medical Center

Melanoma Tumors Use Interferon-Gamma Mutations to Fight Immunotherapy

Melanoma tumors use genetic mutations in a prominent immune response pathway to resist the immunotherapy ipilimumab, researchers from The University of Texas MD Anderson Cancer Center report in the journal Cell....

– University of Texas M. D. Anderson Cancer Center

Presidential Debate: Expert Panel Gives Scientific Analysis of Candidates' Performances

Four expert panelists each day will present their analyses and answer your questions live and face-to-face. This event will be virtual. You can attend with any device -- PC, Mac, iPad, iPhone or Android device (with a webcam) – anywhere with good b...

– Newswise Recommends

Embargo expired on 21-Sep-2016 at 09:00 ET

Duke Team Identifies Blood Biomarkers in Drug-Resistant Cancer Tumor Cells

While searching for a non-invasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies. ...

– Duke Health

Clinical Cancer Research

Immune and Targeted Therapies with Radiation Therapy Improves Outcomes for Melanoma Brain Metastases Patients, Say Moffitt Researchers

In their most recent Annals of Oncology publication, Moffitt researchers sought to determine if patients with melanoma brain metastases treated with immune and targeted therapies had improved outcomes over patients treated with conventional chemother...

– Moffitt Cancer Center

Annals of Oncology

Mount Sinai and Thomas Jefferson University Researchers Receive Falk Foundation Grant to Study Melanoma

Research will illuminate unknown mechanisms of aggressive form of skin cancer...

– Mount Sinai Health System

Neutrophils Are Key to Harnessing Anti-Tumor Immune Response From Radiation Therapy, Study Finds

Combining targeted radiation therapy with a neutrophil stimulant enhances anti-tumor immunity, according to new research into cancer immunology at UT Southwestern Medical Center....

– UT Southwestern Medical Center

PNAS 10.1073/pnas.1613187113

Shedding Light on the Mutational Landscape of the Most Common Pediatric Cancer

Researchers from Columbia University, Rutgers University, and other institutions have identified genomic alterations in pediatric relapsed ALL that cause both therapy resistance and improved clinical response to multi-agent chemotherapy treatment. ...

– Rutgers Cancer Institute of New Jersey

Proceedings of the National Academy of Sciences, Sept-2016

Research Advances in Thyroid Cancer Presented at American Thyroid Association Annual Meeting

During the upcoming 86th Annual Meeting of the American Thyroid Association (ATA), September 21-25, 2016, in Denver, Colorado, many of the poster presentations will report on research advances related to various forms of thyroid cancer, including the...

– American Thyroid Association

Racial Gaps Persist in How Breast Cancer Survivors Function, Feel During Treatment and After

An analysis of the quality of life of several thousand breast cancer survivors in North Carolina found differences in how black and white women functioned and felt physically and spiritually during treatment and two years after diagnosis....

– University of North Carolina Health Care System

Breast Cancer Research and Treatment

Examining Mitochondrial DNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk

Genetic testing of mitochondrial DNA could reveal otherwise unknown ancestry that can influence a person’s risk for certain types of breast cancer, a new study finds. ...

– UT Southwestern Medical Center


At Bat Against Rare Blood Cancers

University of California researchers to hold meeting in San Diego to discuss hematologic malignancies as part of the University of California Hematologic Malignancies Consortium, a first-of-its-kind research group that brings together the five UC hea...

– University of California San Diego Health Sciences


Taking Aim at Triple-Negative Breast Cancer

Rutgers Cancer Institute of New Jersey researchers in the Precision Medicine Program aim to validate a new genomic sequencing approach that may help identify a sub-set of triple-negative breast cancers. The work is supported by a grant from the Val S...

– Rutgers Cancer Institute of New Jersey

NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms

New NCCN Guidelines for Myeloproliferative Neoplasms focus on the treatment of Myelofibrosis, a rare bone marrow cancer; the new recommendations are the most comprehensive treatment guidance available to U.S. clinicians today....

– National Comprehensive Cancer Network® (NCCN®)

MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers

Adaptimmune Therapeutics and The University of Texas MD Anderson Cancer Center announced today they have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer...

– University of Texas M. D. Anderson Cancer Center

Embargo expired on 26-Sep-2016 at 06:30 ET

October Is Breast Cancer Awareness Month

Mount Sinai Experts Offer Tips on Early Detection, Screening, Understanding Risk and Personalized Treatment Options ...

– Mount Sinai Health System

Rutgers Cancer Institute of New Jersey Expands Reach to Greater Newark

A new partnership between Rutgers Cancer Institute of New Jersey and University Hospital in Newark is resulting in the expansion of National Cancer Institute (NCI)-designated Comprehensive Cancer Center services to northern New Jersey....

– Rutgers Cancer Institute of New Jersey

Memorial Sloan Kettering Launches MSK Direct to Expand Access to World-Class Cancer Care

In an effort to expand and streamline patient access to its high-quality cancer care, Memorial Sloan Kettering Cancer Center (MSK) has introduced MSK Direct, a unique program in which MSK collaborates with external employers to simplify how their emp...

– Memorial Sloan Kettering Cancer Center

Embargo expired on 21-Sep-2016 at 08:30 ET

Breast Cancer Scars Do Not Need to Be Visible

Hidden Scar is an advanced approach in which breast surgeons remove cancerous tissue through a single incision made in inconspicuous areas to minimize visible scarring. By using this approach, surgeons are able to preserve a natural-looking breast by...

– PinnacleHealth

Focused Ultrasound Foundation Earns CEO Cancer Gold Standard Accreditation

The CEO Roundtable on Cancer has accredited Focused Ultrasound Foundation in Charlottesville, VA, with the CEO Cancer Gold StandardTM, recognizing its efforts to reduce the risk of cancer for its employees and covered family members. ...

– Focused Ultrasound Foundation

Pazdur to Deliver Keynote at AACI/CCAF Annual Meeting

The 2016 annual meeting of the Association of American Cancer Institutes and the Cancer Center Administrators Forum, will feature Richard Pazdur, MD, Acting Director, Oncology Center of Excellence, United States Food and Drug Administration. ...

– Association of American Cancer Institutes (AACI)

HCI Scientist Receives $1M Award to Fund Cancer Research

Jody Rosenblatt, Ph.D., a cell biologist at Huntsman Cancer Institute and an associate professor of oncological sciences at the University of Utah has been selected as a Howard Hughes Medical Institute (HHMI) Faculty Scholar, HHMI announced today. Th...

– Huntsman Cancer Institute at the University of Utah

Embargo expired on 22-Sep-2016 at 13:00 ET

Higher Education Events

HERO Event Celebrates People Who Take Part in Cancer Clinical Research

The ninth annual Helping to Enhance Research in Oncology event will honor those who take part in cancer clinical trials. The event will also raise awareness for the importance of cancer clinical trials and will offer education sessions about clinical...

– University of New Mexico Comprehensive Cancer Center

Expert Pitch

Data Sharing at a Crossroads: CEO of @SBPdiscovery Speaks Out

– Sanford Burnham Prebys Medical Discovery Institute

Dr. Igor Puzanov of @RoswellPark Cancer Institute Avail. To Comment on Chan/Zuckerberg $30b Pledge for #Medicalresearch

– Roswell Park Cancer Institute





 Edit My Preferences
 Contact Us
 Newswise Home
 Newswise Contact Directory
 Expert Queries
 Presspass Application

More News from:


 University of California San Diego Health Sciences

 UT Southwestern Medical Center

 Newswise Recommends

 Duke Health

 University of Texas M. D. Anderson Cancer Center

 University of Michigan Health System

 Cleveland Clinic

 University of Southampton

 University of California, Los Angeles (UCLA), Health Sciences

 The Rockefeller University Press

 Focused Ultrasound Foundation

Subscribe / Unsubscribe
Edit my preferences

© 2016 Newswise, Inc. All Rights Reserved.

215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417

 Contact Us